Non-interventional, real-world study of patients with early stage, human epidermal growth factor receptor 2 (HER2) positive breast cancer (BC) receiving Trazimera (VESTA)First published 19/12/2019 Last updated 19/12/2019 EU PAS number: EUPAS32829StudyPlanned